While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear ...

Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.

—Investigators in Argentina recently examined a small subset of patients with immunoglobulin G4-related disease (IgG4-RD) and pulmonary findings to learn more about this immune-mediated, multiorgan ...

Men with immunoglobulin G4 (IgG4)-related disease exhibit significantly lower serum lipase levels and a greater likelihood of organ involvement than women, highlighting significant sex-dependent ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. I think the most important thing to know is ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD). An international, ...

The incidence of IgG4-related disease in the U.S. is similar to that of other systemic rheumatic diseases, like systemic sclerosis. In the new analysis, the research team identified 524 cases of ...

Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only ...

WASHINGTON — The B-cell depleting agent inebilizumab (Uplizna) dramatically reduced the risk of flares and increased year-long remission of IgG4-related disease (RD), new research has found. The ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis and ...

Zenas on Monday said obexelimab met the primary endpoint in the Phase 3 study, showing a clinically meaningful and highly statistically significant 56% reduction in the risk of IgG4-RD flare.